Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data.
about
Interventions for hidradenitis suppurativaInterventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence qualitySuperior Efficacy with Ivermectin 1% Cream Compared to Metronidazole 0.75% Cream Contributes to a Better Quality of Life in Patients with Severe Papulopustular Rosacea: A Subanalysis of the Randomized, Investigator-Blinded ATTRACT Study.Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study.Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study.Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials.The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)Comparison of indirubin concentrations in indigo naturalis ointment for psoriasis treatment: a randomized, double-blind, dosage-controlled trial.Measurement properties of adult quality-of-life measurement instruments for eczema: a systematic review.Time, PASI and DLQI of psoriasis patients who "drop out" of clinical trials on etanercept due to "lack of efficacy" - a pooled analysis from ten clinical trials.Conceptualisation, development and validation of T-QoL© (Teenagers' Quality of Life): a patient-focused measure to assess quality of life of adolescents with skin diseases.Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria.Biologics and dermatology life quality index (DLQI) in the Australasian psoriasis population.Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis.A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis.Analysis of Disease Activity Categories in Chronic Spontaneous/Idiopathic Urticaria.Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3.Emollients and moisturisers for eczema.Broader concepts of quality of life measurement, encompassing validation.Management of the psychological comorbidities of dermatological conditions: practitioners' guidelines.Comparative effectiveness of biologic therapies on improvements in quality of life in patients with psoriasis.Comparison of the paper-based and electronic versions of the Dermatology Life Quality Index: evidence of equivalence.The role of community pharmacists in supporting self-management in patients with psoriasis.Comparison of the Dermatology Life Quality Index and the Children's Dermatology Life Quality Index in assessment of quality of life in patients with psoriasis aged 16-17 years.Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study.AIO LQ-0110: a randomized phase II trial comparing oral doxycycline versus local administration of erythromycin as preemptive treatment strategies of panitumumab-mediated skin toxicity in patients with metastatic colorectal cancer.Defining treatment success in rosacea as 'clear' may provide multiple patient benefits: results of a pooled analysis.Quality of life instruments in psoriasis clinical trials.Validation of patient-reported global severity of atopic dermatitis in adults.Sensitivity to change of the Dermatology Life Quality Index in adult females with facial acne vulgaris: a validation study.Discrepancies between the Dermatology Life Quality Index and utility scores.Dermatology Life Quality Index (DLQI) as a psoriasis referral triage tool.NICE approval of adalimumab for moderate-to-severe hidradenitis suppurativa: the end of the beginning for hidradenitis suppurativa therapeutics?Is the DLQI appropriate for medical decision-making in psoriasis patients?Effects of time and recall of patch test results on quality of life (QoL) after testing. Cross-sectional study analyzing QoL in hand eczema patients 1, 5 and 10 years after patch testing.
P2860
Q24186587-927606A9-EF42-4299-90E4-BD9ECC045B29Q28074160-E6D06209-384E-4122-AC7C-B8CC7FAA43ABQ37150175-100630A8-0B3D-4A4E-A3EA-570D540CC9E1Q37345488-A882894A-4939-4271-942C-97EBD070B3CAQ37412781-AD384CD8-C588-485D-8D8A-8F249DFC354BQ37717828-363FEA31-BBD6-43F2-8A4F-11D7EC2BB109Q37718001-1D21C60C-D03F-4939-B710-372E0341CE74Q38372066-EC8EBF6D-1BFB-488B-9DE1-1DB0625F05B2Q38632265-001DECE9-172D-4BB1-87C2-696D948951A3Q38644270-DEBCE897-91F8-439B-935B-0D9E65B5C521Q38649988-7CE50F64-ABD0-4C1A-95EC-54A438DF9366Q38749394-7E157607-68C5-44D3-8D4B-C307CD616E44Q38794282-AA586E15-E63A-48AF-921D-DCE3D04B1743Q38812025-C7CA6307-4801-4ED5-9C66-94581B952F44Q38858335-9F2F780C-AC9A-4CD9-B2E6-AF39D60E1A45Q38907099-9FE58ECA-9982-41D6-9F46-301D0BEE6FE0Q38907492-63FA0F17-6F74-40F0-BEF8-B4920A5BC182Q38976344-7A7DFA20-5E5E-4C53-883B-5816165C461EQ39215992-F51EAEEA-81C8-46FC-A087-8EF9CE86CDBCQ39274236-22655BE5-C04B-4317-B07F-636BF5C0C651Q40261663-70783D42-C7F8-40BC-BAE8-66C45E478D4DQ40361911-391A8CB0-E2C4-453A-BA7B-5AE38F55EF58Q40395123-B9116029-9015-4EA2-9649-34FE36D4965AQ41005141-DD24D039-15C3-477A-9DDB-6B5D01F6E155Q41540546-E22C6456-26C7-4307-8698-F1380693199AQ45070642-A44A50F0-1E4F-46D6-A50C-D4FE8613F0D9Q47138214-40D99AC0-2513-4D3A-B974-4F2D16A7E27AQ47558329-5AC8289F-58B4-479D-BC62-B5621BC95DD4Q47570071-55E02E38-283C-49C9-87EA-2936D6F0EA14Q47695337-6F28EF50-683E-41B0-84D0-ED830ACED201Q47702809-26F137A6-6AD6-4E5A-B85F-09AAA02C283EQ47878354-F0A90DE4-4B60-44BE-883F-D46A8AB2EFC6Q48126276-CB9D5F66-6848-4A09-97C9-F0135FABB137Q48187188-C98B22E6-7DB6-4B5E-8EF1-81E3DBE7C076Q48320518-B4998F39-6588-4BA9-A0A0-2D99EB11A0E4Q50983658-7DD1C28E-3270-4F4A-90FD-7D0D32A39065
P2860
Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Determining the minimal clinic ...... ty Index (DLQI): further data.
@ast
Determining the minimal clinic ...... ty Index (DLQI): further data.
@en
type
label
Determining the minimal clinic ...... ty Index (DLQI): further data.
@ast
Determining the minimal clinic ...... ty Index (DLQI): further data.
@en
prefLabel
Determining the minimal clinic ...... ty Index (DLQI): further data.
@ast
Determining the minimal clinic ...... ty Index (DLQI): further data.
@en
P2093
P356
P1433
P1476
Determining the minimal clinic ...... ty Index (DLQI): further data.
@en
P2093
A Y Finlay
L Camilleri
M K A Basra
P356
10.1159/000365390
P577
2015-01-20T00:00:00Z